Table 1.

Compounds known to induce cyclin D1 degradation in mammalian cell lines.

Compound	Conc.	T286 dependent? a	Cell line	Proteasome inhibitor
All-trans retinoic acid (RA)	4–10 μM	Yes	BEAS-2B, NT2/D1	Lactacystin, LLnLb
Differentiation-inducing factor-1 and 3 (DIF-1 and DIF-3)	30 μM	Yesc	SCC, HeLa	MG132
1-Methyl-4-phenylpyridinium ion (MPP+)	300 nM	Yes	MG63	MG132
hypothemycin	0.5 μg/Ml	N.D.	NIH3T3-DT	Lactacystin
O-methyl deoxybouvardin (RA-VII)	100 nM	N.D.	DLD-1	Lactacystin
GL331	10 μM	N.D.	CL1-5	N-CBZ-L-L-L-AL
Resveratrol	300 μM	N.D.	SW480	LLnLb
Diferuloylmethane (curcumin)	25 μM	N.D.	LnCap, various breast cancer derived	Lactacystin
Lovastatin	10 μM		PC-3-M	LLnLb, d
Aspirin	5 nmol/L	Yese	SW480, HT-29	MG132
Cycloheximide	50 μM	No	MCF-7	MG132
15-deoxy-Δ12,14 prostaglandin J2 (PGJ2)f	5–20 μM	N.D.	MCF-7	MG132, PSII
Ciglitazonef	30–40 μM	N.D.	MCF-7	MG132, PSII
Troglitazonef	40 μM	No	MCF-7	MG132, lactacystin, epoxomicin
Δ2-TGg	5 μM	No	MCF-7	MG132, lactacystin, epoxomicin
Rapamycin	100 nmol/L	Yes	MCF-7, MDA-MB-468	LLnLb
Trichostatin A (TSA)h	1 μM	Yes/noi	MCF-7, MDA-MB-231, KNRK	MG132, ALLN, lactacystin, NLVSj
Sodium chloride (NaCl), calcium chloride (CaCl2), magnesium chloride (MgCl2)	50 mM	Yese	Granta 519	LLnLb, lactacystin, MG132

a) T286 phosphorylation requirement, b) LLnL (ALLN, Calpain inhibitor 1, N-acetyl-leucyl-leucyl-norleucinal, MG101), c) Mirk/Dyrk 1b mediated T288 phosphorylation required, d) Lactacystin failed to abolish lovastatin induced cyclin D1 degradation, e) p38^SAPK2 mediated T286 phosphorylation, f) PGJ2, ciglitazone and troglitazone are PPARγ agonists, g) Δ2-TG is structurally related to troglitazone but lacks PPARγ agonist activity, h) TSA is a prototype HDAC inhibitor, i) partial requirement for GSK3β in TSA induced cyclin D1 degradation, j) NLVS (NIP-leu₃-vinyl sulphone)